Advanced search
Publication Cover
Upsala Journal of Medical Sciences Volume 115, 2010 - Issue 4
Journal homepage
540
Views
14
CrossRef citations to date
0
Altmetric
Original Article

Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients

Meisongzhu Yang Department of Pathology and Pathophysiology, Medical College of Jishou University, Jishou 416000, People's Republic of China; Department of Pathology, Guangxi Medical University, Nanning 530021, People's Republic of China
,
Gang Chen Department of Pathology, Guangxi Medical University, Nanning 530021, People's Republic of China
,
Yiwu Dang Department of Pathology, Guangxi Medical University, Nanning 530021, People's Republic of China
&
Dianzhong Luo Department of Pathology, Guangxi Medical University, Nanning 530021, People's Republic of ChinaCorrespondence[email protected]
Pages 232-237 | Received 01 Jun 2010, Accepted 20 Jul 2010, Published online: 27 Oct 2010

References

  • El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.
  • Jaeck D, Bachellier P, Oussoultzoglou E, Weber JC, Wolf P. Surgical resection of hepatocellular carcinoma. Post-operative outcome and long-term results in Europe: an overview. Liver Transpl. 2004;10:S58–63.
  • Orito E, Mizokami M. Differences of HBV genotypes and hepatocellular carcinoma in Asian countries. Hepatol Res. 2007;37:S33–5.
  • El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33:62–5.
  • Nagai H, Sumino Y. Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. Recent Patents Anticancer Drug Discov. 2008;3:220–6.
  • Colombo M. Screening for cancer in viral hepatitis. Clin Liver Dis. 2001;5:109.
  • Sherman M. Alphafetoprotein: An obituary. J Hepatol. 2001;34:603–5.
  • Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J, Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer. 2003;105:724–32.
  • Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia. 2008;10:1049–56.
  • Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol. 2007;106:112–8.
  • Connor JP, Felder M. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol. 2008;111:330–5.
  • Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010;102:26–38.
  • Chen G, Luo D. Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Ups J Med Sci. 2008;113:297–304.
  • Chen G, Luo D. Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India. 2008;21:275–8.
  • Shen HW, Gao SL, Wu YL, Peng SY. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol. 2005;11:5926–30.
  • Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699–703.
  • Hwang SL, Lin CL, Cheng CY, Lin FA, Lieu AS, Howng SL, Serum concentration of soluble decoy receptor 3 in glioma patients before and after surgery. Kaohsiung J Med Sci. 2004;20:124–7.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.